SAGE Therapeutics (SAGE) Tops Q1 EPS by 16c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.68), $0.16 better than the analyst estimate of ($1.84). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AXT appoints Tracy Liu to its board of directors
• Hermès can regain momentum despite China weakness, Jefferies says